louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00004688: Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Mixed Gliomas
Glioblastoma Multiforme
Recurrent Brain Tumor
Keywords: adult anaplastic astrocytoma
adult anaplastic oligodendroglioma
adult brain stem glioma
adult brain tumor
adult glioblastoma multiforme
adult infiltrating astrocytoma
brain tumor
genetic condition
miscellaneous sites/terms
mixed gliomas
nervous tissue tumors
oncologic disorders
rare disease
recurrent adult brain tumor
Lead sponsor: FDA Office of Orphan Products Development
Sponsor class: FED
First posted: 2000-02-25
Enrollment: 35
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: OBJECTIVES:

I. Assess the clinical response of patients with refractory or recurrent brain neoplasms treated with carmustine, streptozocin, and mercaptopurine.

Detailed description: PROTOCOL OUTLINE:

Patients receive mercaptopurine IV on days 1-3, carmustine by continuous infusion on days 3-5, and streptozocin IV over 20 minutes on days 2-5. Patients receive treatment every 42 days, for up to 4 courses.

Completion date provided represents the completion date of the grant per OOPD records

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Histologically proven refractory or recurrent brain neoplasms Glioblastoma multiforme Anaplastic astrocytoma Gliosarcoma Anaplastic oligodendroglioma Mixed anaplastic glioma Unequivocally progressive primary brainstem tumors following primary therapy Measurable disease --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: At least 4 weeks since prior chemotherapy At least 6 weeks since prior nitrosoureas or mitomycin Endocrine therapy: Not specified Radiotherapy: Prior radiotherapy allowed Surgery: Prior surgery allowed --Patient Characteristics-- Age: Not specified Performance status: ECOG 0-2 Karnofsky 60-100% Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT no greater than 4 times normal Renal: Creatinine no greater than 2.0 mg/dL Pulmonary: FEV1 greater than 1 L if symptomatic pulmonary disease present Other: No other concurrent malignancies Not pregnant or lactating Negative pregnancy test Fertile patients must use effective contraception

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Emory University
name: Mark R. Gilbert
role: STUDY_CHAIR
References:
Clinical trial NCT03820388: Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia
Official title: Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Surgery
Keywords: Etomidate
Propofol
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2019-01-29
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients in 3 cohorts will be administered 30 second bolus by manual hand push
Primary purpose: SUPPORTIVE_CARE

Brief summary: Comparison of Etomidate plus Propofol vs. Propofol or Etomidate alone during induction of anesthesia.

Detailed description: Comparison of Etomidate plus Propofol vs. Propofol or Etomidate alone during induction of anesthesia. The specific aims are testing patient reactions during induction, and in the post-anesthesia care unit (PACU).

Eligibility criteria: Inclusion Criteria:

* Patients scheduled for elective non-cardiac surgery
* ASA physical status of 2 or 3
* Age equal to or greater than 18 years old

Exclusion Criteria:

* Adults unable to provide consent
* Age less than 18 years old
* Pregnant women
* Prisoners
* Difficult airway
* Morbid Obesity
* Preoperative sedation use
* Severe Cardiac, pulmonary and liver disease
* Hypotension and shock
* Emergency surgeries
* Allergy to propofol or etomidate

Primary outcomes:
measure: Blood Pressure
timeFrame: 10 minutes after induction (intraoperative)
measure: Heart Rate
timeFrame: 10 minutes after induction (intraoperative)
Secondary outcomes:
measure: Pain at Injection Site
timeFrame: intraoperative
measure: Myoclonic Movements
timeFrame: intraoperative
measure: Post-operative Nausea and Vomiting
timeFrame: 24 hours post-operation
measure: Sedation Depth
timeFrame: 30 minutes post-induction
measure: Eyelash Reflex Disappear Time
timeFrame: Post induction, up to 1 hour
measure: Intubation Time
timeFrame: Up to 2 hours
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis Medical Center
state: California
Study officials:
affiliation: University of California, Davis
name: Hong Liu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01017588: PSU Lumbar Support for Prevention of Low Back Pain in Rubber Tapper
Official title: Lumbar Support for Low Back Pain Prevention in Rubber Tapper
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Low Back Pain
Keywords: lumbar support
rubber tapper
Lead sponsor: Prince of Songkla University
Sponsor class: OTHER
First posted: 2009-11-20
Enrollment: 200
Sex: ALL
Minimum age (years): 15
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aims to evaluate the efficacy of lumbar support for low back pain prevention in rubber tapper. The investigators will randomized the participants(rubber tapper) into 2 groups;lumbar support and no support.The participant will be instructed for brace use. The sample size required are 200 subjects with 100 in each group. The subject will be evaluated every 3 month for the incidence of low back pain and quality of life after using the support.


Eligibility criteria: Inclusion Criteria:

* current rubber tapper

Exclusion Criteria:

* underlying rheumatologic condition
* previous significant low back pain
* previous back surgery

Primary outcomes:
measure: incidence of low back pain
timeFrame: 6 month, 1 and 2 years
Secondary outcomes:
measure: Roland Moris score
timeFrame: 6 month, 1 and 2 years
Other outcomes:
Locations:
city: Hat Yai
country: Thailand
facility: Prince of Songkla University
state: Songkhla
Study officials:
affiliation: Department of Orthopaedic Surgery, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand
name: Boonsin Tangtrakulwanich, MD.,Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06924788: Video-Conferenced Stress Management and Relaxation Training (VSMART) For Alabama Breast Cancer Survivors
Official title: Video-Conferenced Stress Management and Relaxation Training (VSMART) For Alabama Breast Cancer Survivors
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Keywords: Breast Cancer
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2025-04-11
Enrollment: 25
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: In a sample of Alabama breast cancer survivors, the proposed study tests the feasibility and acceptability of a stress management program that has been shown to improve health and wellbeing in a general population of patients with a history of breast cancer. The study will also get feedback (e.g., implementation barriers and facilitators) from relevant stakeholders.


Eligibility criteria: Inclusion Criteria:

* Breast cancer survivor
* Currently living in Alabama
* Living in neighborhood with high deprivation index

Exclusion Criteria:

* Non-Alabama resident
* No history of breast cancer
* Living in neighborhood with low deprivation index

Primary outcomes:
measure: Percentage of people enrolled out of contacted
timeFrame: At time of enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
Study officials:
affiliation: University of Alabama at Birmingham
name: Chloe Taub, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06497088: A Clinical Study to Evaluate the Ultrasonic Detection of a Novel Nasogastric Tube in the Human Body.
Official title: A Clinical Study to Evaluate the Ultrasonic Detection of a Novel Nasogastric Tube in the Human Body
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Nasogastric Tube Placement
Lead sponsor: Nasotrak Medical Pte Ltd
Sponsor class: INDUSTRY
First posted: 2024-07-11
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this study is to evaluate the safety, efficacy and accuracy of the Nasotrak System in an adult patient population.


Eligibility criteria: Inclusion Criteria:

* Adults greater than 18 years of age
* Able to provide informed consent or have a legally authorized representative available to provide informed consent in English
* Clinically requiring a 12 Fr NG/OG tube with X-ray confirmation per standard protocol

Exclusion Criteria:

* Female subjects of childbearing age with known pregnancy or lactating.
* Prisoners.
* Unable to consent in English.
* Subjects/ volunteers with pacemakers or life-sustaining devices in the body such as ICD.
* Subjects with a history of:
* Esophageal varices or ulcers.
* Upper airway obstruction.
* Upper GI stenosis or obstruction.
* Trauma involving sinuses, nares face or neck that would prevent nasogastric (NG) or oral tube insertion.
* Deformities of the sinus cavities and/or skull base.
* Esophageal cancer or neoplasm.

Primary outcomes:
measure: Evaluate the effectiveness of detecting Nasotrak's nasogastric tube's distal tip using Nasotrak's ultrasound verification algorithm compared to X-ray.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Wayne
country: United States
facility: Parkview Regional Medical Center
state: Indiana
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
Study officials:
affiliation: Nasotrak Medical Pte Ltd
name: David Tan, Beng
role: STUDY_CHAIR
References:
Clinical trial NCT04387188: Return to Play Criteria After Shoulder Dislocation in Upper Limb Athletes: Critical Analysis Between the Habits of Medical Professionals and the Literature
Official title: Return to Play Criteria After Shoulder Dislocation in Upper Limb Athletes: Critical Analysis Between the Habits of Medical Professionals and the Literature
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Return to Sport
Survey and Questionnaire
Shoulder Dislocation
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2020-05-13
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The target population consisted of French-speaking physicians in orthopedic surgery, physical medicine and rehabilitation or sports medicine.

Brief summary: Purpose: Identify the criteria employed by sports medicine specialists in assessing the aptitude/inaptitude of an overhead athlete to return to competition following an antero-internal dislocation of the glenohumeral joint that has been operated or not.

Materials and methods: The target population consisted of French-speaking physicians in orthopedic surgery, physical medicine and rehabilitation or sports medicine. This study was conducted by the means of a questionnaire. The list of the most relevant criteria to be included in the questionnaire was established following a literature review.


Eligibility criteria: Inclusion Criteria:

* Professions: physicians in orthopedic surgery, physical medicine and rehabilitation or sports medicine.
* Language: French

Exclusion Criteria:

* Other professions

Primary outcomes:
measure: The return to play criteria
timeFrame: The questionnaire will last 15 minutes at most
Secondary outcomes:
Other outcomes:
Locations:
city: Liège
country: Belgium
facility: Gofflot Amandine
Study officials:
References:
Clinical trial NCT02038088: The Effect of General Anesthesia Immunosuppressive on Hepatitis B Virus Replication
Official title: The Effect of General Anesthesia Immunosuppressive on Hepatitis B Virus Replication
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HBV Infection
Keywords: Need general anesthesia
Lead sponsor: Southwest Hospital, China
Sponsor class: OTHER
First posted: 2014-01-16
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with HBV infection receive surgery under general anesthesia

Brief summary: The purpose of this study is to determine whether the general anesthesia immunosuppressive could effect hepatitis B Virus replication

Detailed description: The change of immune state can influence HBV replication or elimination, it has been reported that a certain degree of immunosuppression occured after general anesthesia. In this study we detect the cytotoxic T lymphocyte(CTL) count and activity, interferon-γ(IFN-γ) and HBV-DNA content form the HBV patient who will accept general anesthesia. Our purpose is to evaluate the influence of general anesthesia immunosuppressive on HBV replication. If the results show that HBV-DNA quantity increases, so the patients might be given anti-HBV drugs or immune enhancer; otherwise it is indicated the general anesthesia immunosuppressive don't influence HBV replication.

Eligibility criteria: Inclusion Criteria:

1. American Society of Anesthesiologists（ASA） Ⅰ - Ⅱ;
2. ability to compliance the research plan;
3. volunteered and signed for the study ;
4. HBsAg positive, no serious system disease (heart: New York Heart Association（NYHA） class Ⅰ - Ⅱ, lung: vital capacity（VC）% or maximal voluntary ventilation（MVV）%\>71, forced expiratory volume at one second（FEV1.0）%\>61, arterial oxygen saturation（SaO2）%\>94, arterial partial pressure of oxygen（PaO2）\>75 mmHg, arterial carbondioxide partial pressure（PaCO2）\<45mmHg, liver:child-pugh class A - B and kidney: chronic kidney disease（CKD）stage 1-3);
5. receive under general anesthesia (including gynecology, orthopedics,general surgery and urology department).

Exclusion Criteria:

1. ASA\>Ⅱ;
2. tumor patients
3. can't collaborate;

Primary outcomes:
measure: HBV-DNA
timeFrame: with in the first 5 days after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: ChongQing
country: China
facility: Department of Anesthesiology, Southwest Hospital Third Military Medical University
state: Chongqing
Study officials:
affiliation: Department of Anesthesiology, Southwest Hospital Third Military Medical University
name: Lu KZ, PhD
role: STUDY_DIRECTOR
References:
citation: Quan J, Chen X, Tang X, Liu X, Li J, Yi B, Li P, Lu K, Gu J. Effects of General Anesthesia on Changes of Serum Hepatitis B Virus-DNA Levels in Infected Patients Underwent Non-Hepatobiliary Minimally Invasive Surgery: A Pilot Observational Study. Infect Drug Resist. 2022 Nov 11;15:6631-6640. doi: 10.2147/IDR.S379350. eCollection 2022.
Clinical trial NCT04554888: Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor
Official title: Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Itch
Lead sponsor: Aalborg University
Sponsor class: OTHER
First posted: 2020-09-18
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: In this experiment the investigators would like to assess if papain induces an itch sensation comparable to the itch sensation induced by cowhage and to confirm that the mechanism of action of papain follows the non-histaminergic pathway.


Eligibility criteria: Inclusion Criteria:

* Healthy men and women
* 18-60 years
* Speak and understand English

Exclusion Criteria:

* Pregnancy or lactation
* Drug addiction defined as any use of cannabis, opioids or other addictive drugs
* Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. neuropathy, muscular pain in the upper extremities, etc.).
* Lack of ability to cooperate
* Current use of medications that may affect the trial such as antihistamines, antipsychotics and pain killers, as well as systemic or topical steroids.
* Skin diseases
* Moles, scars or tattoos in the area to be treated or tested.
* Hypersensitivity to papaya and mango fruit, cashew nuts, rubber latex
* Consumption of alcohol or painkillers 24 hours before the study days and between these
* Acute or chronic pain
* Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)

Primary outcomes:
measure: Superficial blood perfusion
timeFrame: 15 minutes
measure: Measuring itch intensity by computerized Visual Analog Scale Scoring
timeFrame: 15 minutes
measure: Measuring pain intensity by computerized Visual Analog Scale Scoring
timeFrame: 15 minutes
measure: Measuring Alloknesis
timeFrame: 15 minutes
Secondary outcomes:
measure: Measurement of Cold Detection Thresholds (CDT)
timeFrame: 15 minutes
measure: Measurement of Cold PainThresholds (CPT)
timeFrame: 15 minutes
measure: Measurement of Heat Pain Thresholds (HPT)
timeFrame: 15 minutes
measure: Measurement of Warm Detection Thresholds (WDT)
timeFrame: 15 minutes
measure: Measurement of Pain to Supra-threshold Heat Stimuli
timeFrame: 15 minutes
measure: Measurement of Mechanical Pain Thresholds (MPT)
timeFrame: 15 minutes
measure: Measurement of Mechanical Pain Sensitivity (MPS)
timeFrame: 15 minutes
measure: Touch Pleasantness (TP)
timeFrame: 15 minutes
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Aalborg University
state: Nordjylland
Study officials:
References:
Clinical trial NCT02723188: Modulation of Fear Extinction Processes Using Transcranial Electrical Stimulation
Official title: Modulation of Fear Extinction Processes Using Transcranial Electrical Stimulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stress Related Disorder
Anxiety
Lead sponsor: Tel Aviv University
Sponsor class: OTHER
First posted: 2016-03-30
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of this study is to examine the effects of transcranial electrical stimulation on processes associated with fear extinction in healthy humans.

Detailed description: Research links the processes of fear conditioning and extinction to the treatment of anxiety and stress-related disorders. Moreover, considerable translational research examines the neural correlates of these processes. However, virtually no research in humans manipulates neural correlates of these processes, which limits basic-clinical integration. The present study aimed to use transcranial electrical stimulation (tES) to modulate processes associated with fear extinction in order to assess the potential utility of tES in enhancing exposure-based treatment. To this end, healthy participants underwent a three-day fear conditioning and extinction paradigm. Participants were randomly assigned into 3 groups, differing in terms of tES applied during the extinction learning phase (Day 2) and targeting the medial prefrontal cortex: 1) direct current (DC) stimulation, aimed at enhancing extinction learning; 2) alternate current (AC) stimulation, aimed at interfering with reconsolidation of the fear memory activated during the extinction phase; and 3) sham stimulation. The outcome measures (outlined next) involve the assessment of extinction recall during a test phase (Day 3). Successful modulation of extinction learning by tES would be reflected in enhanced extinction recall.

Eligibility criteria: Inclusion Criteria:

Exclusion Criteria:

* Self-reported major psychiatric condition
* Screening specific for electrical stimulation (psychotropic medication, metal implants in head, epilepsy or seizure history)

Primary outcomes:
measure: Galvanic Skin Response (GSR)
timeFrame: During three-day experimental task
Secondary outcomes:
measure: Self-reported Fear Rankings
timeFrame: During three-day experimental task
Other outcomes:
Locations:
Study officials:
References:
citation: Abend R, Jalon I, Gurevitch G, Sar-El R, Shechner T, Pine DS, Hendler T, Bar-Haim Y. Modulation of fear extinction processes using transcranial electrical stimulation. Transl Psychiatry. 2016 Oct 11;6(10):e913. doi: 10.1038/tp.2016.197.
Clinical trial NCT04301388: Management of Threatened Preterm Labor by Cervical Length-based Approach or Conventional Approach
Official title: A Comparison of the Effectiveness in Management of Threatened Preterm Labor Between Cervical Length-based Approach and Conventional Approach: A Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Preterm Delivery Within 7 Day After Admission
Lead sponsor: Chiang Mai University
Sponsor class: OTHER
First posted: 2020-03-10
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To compare the effectiveness of treatment of threatened preterm labor between transvaginal cervical length-based approach and conventional approach (Per vaginal examination)


Eligibility criteria: Inclusion Criteria:

* Pregnant with symptoms of threatened preterm labor which refer to regular uterine contractions at least 1 time in every 10 minutes and persist for 30 minute without cervical dilatation or cervical dilation ≤ 1 cm and \< 80% of effacement.
* Age ≥ 18 years
* Singleton pregnancy
* 24 0/7 - 33 6/7 weeks of gestation
* Uneventful antenatal care or low-risk pregnancies

Exclusion Criteria:

* The definitive diagnosis of true labor
* Proceed to the active phase of labor
* Age \< 18 years
* Multiple pregnancies
* \< 24 or ≥ 34 weeks of gestation
* Fetal chromosomal or structural abnormalities
* Abnormal fetal growth
* Abnormal amniotic fluid
* Evidence of placenta previa
* Significant vaginal bleeding that cannot be ruled out placenta previa
* Evidence of rupture of membranes
* Evidence of intrauterine infection
* Evidence of uterine malformation
* Evidence of lethal fetal malformation
* Unable to communicate or understand the information of the study

Primary outcomes:
measure: Number of cases with delivery within 7 day after admission
timeFrame: From admission to no uterine contraction in 10 minute
Secondary outcomes:
measure: The number of tocolysis courses, length of hospital stay
timeFrame: From admission to no uterine contraction in 10 minute
measure: The number of steroid courses
timeFrame: From admission to no uterine contraction in 10 minute
Other outcomes:
Locations:
city: Chiang Mai
country: Thailand
facility: Kuntharee Traisrisilp
city: ChiangMai
country: Thailand
facility: Maharaj Nakorn ChiangMai Hospital
Study officials:
References: